Neurex Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurex Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (395)	1/15/1998 7:45:00 PM
From: John McCarthy	of 449

NeuroInvestment: Sorry you had to wait for me, and perhaps others, to catch up. In order, (1) Can't apply numbers to my matrix (prior post) because NXCO is blind to the specific numbers of this interim report. i.e. no detail available (2) Nothwithstanding the numbers, it would be logical to think that if there were a problem with "intent to treat" population vs "evaluable" population, NXCO, to stay in sync with current FDA relationship , would maintain a patient accrual so that evaluable population count was satisfactory. (3) Neuropsychiatric side effects do not seem to be apparent with #Z# as opposed to competitive NMDA antagonists. (4) Blood pressure issues have more to do with the use of #Z# with respect to head trauma. With respect to this indication the doses of #z# are much higher i.e. 70 mg per day. (5) Competitors : NTIIC (Neurobiological Tech) has a Phase 2 coming out, if OK they'll seek partner and run to Phase 3. Sept . Cash 2.3 Qtr Cash out 1.3 I hope I got your points and will be able to contribute constructively to this puppy. Regards, John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next